Inebilizumab  (Synonyms: 伊奈利珠单抗)

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research^[1].

Inebilizumab is derived from the mouse anti-human mAb HB12b, which had already shown impressive activity in depletion of B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)^[1].
Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells^[1].
Inebilizumab demonstrates equal or better activity than Rituximab (HY-P9913) in depletion of human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1299440-37-1

液体

Colorless to light yellow

伊奈利珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107.  [Content Brief]

  [2]. Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22.  [Content Brief]